183 related articles for article (PubMed ID: 26799322)
1. Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.
Mehta K; Appleman L; Wang H; Tarhini AA; Parikh RA
PLoS One; 2016; 11(1):e0147153. PubMed ID: 26799322
[TBL] [Abstract][Full Text] [Related]
2. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
Khong B; Lawson BO; Ma J; McGovern C; Van Atta JK; Ray A; Khong HT
BMC Cancer; 2018 Oct; 18(1):1007. PubMed ID: 30342473
[TBL] [Abstract][Full Text] [Related]
3. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow S; Galvis V; Pillai M; Leach R; Keene E; Spencer-Shaw A; Shablak A; Shanks J; Liptrot T; Thistlethwaite F; Hawkins RE
J Immunother Cancer; 2016; 4():67. PubMed ID: 27777776
[TBL] [Abstract][Full Text] [Related]
4. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.
Alwan LM; Grossmann K; Sageser D; Van Atta J; Agarwal N; Gilreath JA
Target Oncol; 2014 Mar; 9(1):63-71. PubMed ID: 23609056
[TBL] [Abstract][Full Text] [Related]
5. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
[TBL] [Abstract][Full Text] [Related]
6. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the charges, safety, and mortality of percutaneous renal thermal ablation using the nationwide inpatient sample.
Welch BT; Brinjikji W; Schmit GD; Kurup AN; El-Sayed AM; Cloft HJ; Thompson RH; Callstrom MR; Atwell TD
J Vasc Interv Radiol; 2015 Mar; 26(3):342-7. PubMed ID: 25534634
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
9. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
10. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Eisner JR; Beebe KD; Mayhew GM; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Mooney J; Milburn MV; Foureau D; White RL; Amin A; Milla ME
Cancer Res Commun; 2022 Aug; 2(8):894-903. PubMed ID: 36923304
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Lam ET; Wong MK; Agarwal N; Redman BG; Logan T; Gao D; Flaig TW; Lewis K; Poust J; Monk P; Jarkowski A; Sendilnathan A; Bolden M; Kuzel TM; Olencki T
J Immunother; 2014 Sep; 37(7):360-5. PubMed ID: 25075565
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Influence of Hospital Volume on Inpatient Outcomes Following Hospitalization for Status Epilepticus.
Syed MJ; Zutshi D; Khawaja A; Basha MM; Marawar R
Neurocrit Care; 2023 Feb; 38(1):26-34. PubMed ID: 36522515
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study.
Lawson KA; Saarela O; Abouassaly R; Kim SP; Breau RH; Finelli A
Eur Urol; 2017 Sep; 72(3):379-386. PubMed ID: 28511884
[TBL] [Abstract][Full Text] [Related]
14. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
[TBL] [Abstract][Full Text] [Related]
16. Hospital volume and outcomes of robot-assisted partial nephrectomy.
Xia L; Pulido JE; Chelluri RR; Strother MC; Taylor BL; Raman JD; Guzzo TJ
BJU Int; 2018 Jun; 121(6):900-907. PubMed ID: 29232025
[TBL] [Abstract][Full Text] [Related]
17. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
[TBL] [Abstract][Full Text] [Related]
18. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
19. Discharge dispositions, complications, and costs of hospitalization in spinal cord tumor surgery: analysis of data from the United States Nationwide Inpatient Sample, 2003-2010.
Sharma M; Sonig A; Ambekar S; Nanda A
J Neurosurg Spine; 2014 Feb; 20(2):125-41. PubMed ID: 24286530
[TBL] [Abstract][Full Text] [Related]
20. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock.
Shaefi S; O'Gara B; Kociol RD; Joynt K; Mueller A; Nizamuddin J; Mahmood E; Talmor D; Shahul S
J Am Heart Assoc; 2015 Jan; 4(1):e001462. PubMed ID: 25559014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
